AnaptysBio (NASDAQ:ANAB) Stock Rating Upgraded by Wall Street Zen

AnaptysBio (NASDAQ:ANAB) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report issued on Saturday.

A number of other research analysts have also weighed in on the stock. HC Wainwright raised their price target on shares of AnaptysBio from $38.00 to $59.00 and gave the company a “buy” rating in a research note on Tuesday, September 30th. Guggenheim raised their target price on AnaptysBio from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Wedbush lifted their price target on AnaptysBio from $45.00 to $70.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 15th. JPMorgan Chase & Co. boosted their price target on AnaptysBio from $42.00 to $80.00 and gave the stock an “overweight” rating in a research report on Thursday, July 24th. Finally, UBS Group restated a “neutral” rating and issued a $20.00 price objective (up previously from $18.00) on shares of AnaptysBio in a report on Tuesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $61.30.

AnaptysBio Stock Performance

Shares of NASDAQ ANAB opened at $39.65 on Friday. The firm has a fifty day moving average of $28.81 and a 200 day moving average of $24.73. The firm has a market cap of $1.10 billion, a PE ratio of -14.06 and a beta of 0.16. AnaptysBio has a one year low of $12.21 and a one year high of $40.96.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $1.58. The business had revenue of $76.32 million for the quarter, compared to the consensus estimate of $15.83 million. AnaptysBio had a negative net margin of 49.94% and a negative return on equity of 1,101.24%. On average, equities analysts predict that AnaptysBio will post -6.08 EPS for the current fiscal year.

Institutional Trading of AnaptysBio

A number of hedge funds and other institutional investors have recently modified their holdings of ANAB. Skandinaviska Enskilda Banken AB publ raised its holdings in shares of AnaptysBio by 333.1% during the 3rd quarter. Skandinaviska Enskilda Banken AB publ now owns 145,191 shares of the biotechnology company’s stock worth $4,446,000 after acquiring an additional 111,668 shares during the period. Profund Advisors LLC acquired a new stake in AnaptysBio during the third quarter worth about $201,000. Bessemer Group Inc. raised its stake in AnaptysBio by 950.0% during the third quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 1,292 shares during the period. AlphaQuest LLC purchased a new position in AnaptysBio during the third quarter worth about $277,000. Finally, New York State Common Retirement Fund boosted its holdings in AnaptysBio by 33.6% in the 3rd quarter. New York State Common Retirement Fund now owns 10,586 shares of the biotechnology company’s stock valued at $324,000 after purchasing an additional 2,662 shares during the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.